JP2018529341A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529341A5 JP2018529341A5 JP2018514955A JP2018514955A JP2018529341A5 JP 2018529341 A5 JP2018529341 A5 JP 2018529341A5 JP 2018514955 A JP2018514955 A JP 2018514955A JP 2018514955 A JP2018514955 A JP 2018514955A JP 2018529341 A5 JP2018529341 A5 JP 2018529341A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- host cell
- inactivated
- gene
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022003590A JP7493540B2 (ja) | 2015-09-22 | 2022-01-13 | Ｆｃ含有タンパク質の発現 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562222187P | 2015-09-22 | 2015-09-22 | |
| US62/222,187 | 2015-09-22 | ||
| PCT/US2016/052962 WO2017053482A1 (en) | 2015-09-22 | 2016-09-21 | Expression of fc-containing proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022003590A Division JP7493540B2 (ja) | 2015-09-22 | 2022-01-13 | Ｆｃ含有タンパク質の発現 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529341A JP2018529341A (ja) | 2018-10-11 |
| JP2018529341A5 true JP2018529341A5 (enExample) | 2019-11-07 |
| JP7010812B2 JP7010812B2 (ja) | 2022-02-10 |
Family
ID=57068227
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018514955A Active JP7010812B2 (ja) | 2015-09-22 | 2016-09-21 | Ｆｃ含有タンパク質の発現 |
| JP2022003590A Active JP7493540B2 (ja) | 2015-09-22 | 2022-01-13 | Ｆｃ含有タンパク質の発現 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022003590A Active JP7493540B2 (ja) | 2015-09-22 | 2022-01-13 | Ｆｃ含有タンパク質の発現 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11591382B2 (enExample) |
| EP (2) | EP3699269A1 (enExample) |
| JP (2) | JP7010812B2 (enExample) |
| KR (1) | KR102645625B1 (enExample) |
| CN (1) | CN108138147B (enExample) |
| AU (1) | AU2016329001A1 (enExample) |
| BR (1) | BR112018005464A2 (enExample) |
| CA (1) | CA2996691A1 (enExample) |
| HK (1) | HK1255456A1 (enExample) |
| IL (1) | IL257887A (enExample) |
| MX (1) | MX2018003445A (enExample) |
| WO (1) | WO2017053482A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3699269A1 (en) | 2015-09-22 | 2020-08-26 | F. Hoffmann-La Roche AG | Expression of fc-containing proteins |
| CN109321570A (zh) * | 2017-07-31 | 2019-02-12 | 中国科学院上海生命科学研究院 | 用于体外抗体类型转换的方法及试剂盒 |
| JP2021519073A (ja) | 2018-03-29 | 2021-08-10 | ジェネンテック， インコーポレイテッド | 哺乳動物細胞におけるラクトジェニック活性の制御 |
| CN112074604A (zh) * | 2018-05-04 | 2020-12-11 | 西格马-奥尔德里奇有限责任公司 | 具有修饰的宿主细胞蛋白概况的工程改造的细胞 |
| CN114555792A (zh) | 2019-10-15 | 2022-05-27 | 伊莱利利公司 | 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系 |
| EP4217383A1 (en) | 2020-09-22 | 2023-08-02 | Bristol-Myers Squibb Company | Methods for producing therapeutic proteins |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US30985A (en) | 1860-12-18 | Thomas l | ||
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US6239328B1 (en) | 1992-10-05 | 2001-05-29 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6037525A (en) | 1996-08-01 | 2000-03-14 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6245974B1 (en) | 1997-08-06 | 2001-06-12 | North Carolina State University | Matrix attachment regions |
| US6177612B1 (en) | 1998-07-31 | 2001-01-23 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada | Matrix attachment regions |
| WO2000018938A1 (en) | 1998-09-29 | 2000-04-06 | Pioneer Hi-Bred International, Inc. | Mar/sar elements flanking rsyn7-driven construct |
| KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
| WO2002048379A1 (en) | 2000-12-15 | 2002-06-20 | Pangen Biotech Inc. | Expression vector for animal cell containing nuclear matrix attachment region fo interferon beta |
| DK1395669T3 (da) | 2001-01-26 | 2009-11-16 | Selexis Sa | Matriks bindingsregioner og fremgangsmåder til anvendelse af disse |
| US7326567B2 (en) | 2003-11-12 | 2008-02-05 | Schering Corporation | Plasmid system for multigene expression |
| DK1771482T3 (da) | 2004-07-22 | 2014-10-20 | Genentech Inc | HER2-antistofsammensætning |
| KR20080025174A (ko) * | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
| US20100204055A1 (en) | 2008-12-05 | 2010-08-12 | Bonner-Ferraby Phoebe W | Autoantibody detection systems and methods |
| ES2550761T3 (es) * | 2009-11-25 | 2015-11-12 | Novo Nordisk A/S | Método para producción de polipéptidos |
| US8986956B2 (en) * | 2010-11-04 | 2015-03-24 | Korea Research Institute Of Bioscience And Biotechnology | Method for producing human epidermal growth factor in large volume from yeast |
| JP6454547B2 (ja) | 2011-07-06 | 2019-01-16 | ゲンマブ エー／エス | 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節 |
| DK2729482T3 (en) | 2011-07-08 | 2018-05-07 | Merck Sharp & Dohme | PROCEDURE FOR CLEANING FC-FUSION PROTEIN |
| CN103717729B (zh) * | 2011-07-08 | 2017-11-21 | 动量制药公司 | 细胞培养方法 |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| CN106459995B (zh) * | 2013-11-07 | 2020-02-21 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| KR102170502B1 (ko) * | 2013-12-11 | 2020-10-28 | 리제너론 파마슈티칼스 인코포레이티드 | 게놈의 표적화된 변형을 위한 방법 및 조성물 |
| EP3699269A1 (en) | 2015-09-22 | 2020-08-26 | F. Hoffmann-La Roche AG | Expression of fc-containing proteins |
-
2016
- 2016-09-21 EP EP19214172.9A patent/EP3699269A1/en active Pending
- 2016-09-21 WO PCT/US2016/052962 patent/WO2017053482A1/en not_active Ceased
- 2016-09-21 JP JP2018514955A patent/JP7010812B2/ja active Active
- 2016-09-21 MX MX2018003445A patent/MX2018003445A/es unknown
- 2016-09-21 CA CA2996691A patent/CA2996691A1/en active Pending
- 2016-09-21 AU AU2016329001A patent/AU2016329001A1/en not_active Abandoned
- 2016-09-21 CN CN201680054785.8A patent/CN108138147B/zh active Active
- 2016-09-21 BR BR112018005464-0A patent/BR112018005464A2/en not_active Application Discontinuation
- 2016-09-21 HK HK18114629.0A patent/HK1255456A1/zh unknown
- 2016-09-21 US US15/761,887 patent/US11591382B2/en active Active
- 2016-09-21 KR KR1020187010960A patent/KR102645625B1/ko active Active
- 2016-09-21 EP EP16775943.0A patent/EP3353288A1/en not_active Withdrawn
-
2018
- 2018-03-05 IL IL257887A patent/IL257887A/en unknown
-
2022
- 2022-01-13 JP JP2022003590A patent/JP7493540B2/ja active Active
-
2023
- 2023-01-18 US US18/156,215 patent/US12421299B2/en active Active
-
2025
- 2025-08-29 US US19/314,813 patent/US20260049120A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529341A5 (enExample) | ||
| AU2024202046B2 (en) | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof | |
| Hodgson | The pandemic pipeline | |
| Steeland et al. | A new venue of TNF targeting | |
| Gaudinski et al. | Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults | |
| Thran et al. | mRNA mediates passive vaccination against infectious agents, toxins, and tumors | |
| Puig | The role of IL 23 in the treatment of psoriasis | |
| Ma et al. | TNF inhibitor therapy for rheumatoid arthritis | |
| Monaco et al. | Anti-TNF therapy: past, present and future | |
| Harrison et al. | Research strategies to improve snakebite treatment: Challenges and progress | |
| ZA202210065B (en) | Interleukin-21 muteins and methods of treatment | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
| HRP20201031T1 (hr) | Anti-ctla-4 protutijela i postupci njihove upotrebe | |
| JP2017101068A5 (enExample) | ||
| JP2017508744A5 (enExample) | ||
| UA105009C2 (uk) | Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу | |
| JP2017529326A5 (enExample) | ||
| JP2014534169A5 (enExample) | ||
| US20210009678A1 (en) | Methods and compositions for allergic disorders | |
| US20220220223A1 (en) | Treatment of allergic diseases with chimeric protein | |
| Wu et al. | New insights into the role of cellular senescence and its therapeutic implications in ocular diseases | |
| Tolstrup et al. | Development of recombinant human polyclonal antibodies for the treatment of complex human diseases | |
| Lu et al. | Neutralizing Antibodies vs. Viruses: Interacting Mechanisms and Escape Tactics | |
| Sterry et al. | Is ‘class effect’relevant when assessing the benefit/risk profile of a biologic agent? |